Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Burkitt Lymphoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Down Syndrome 2Childhood Acute Promyelocytic Leukemia With PML-RARA 1

Interventions

Cytarabine 5Vincristine 3Thioguanine 3Methotrexate 3Mercaptopurine 3Daunorubicin 3Cyclophosphamide 3prednylidene 2pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2azathiopurine 2auricularum 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2Leucovorin 2Etoposide 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2Asparaginase 2deltacortene 1blinatumomab 1Radiotherapy 1Radiation 1Prednisone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Mitoxantrone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Down Syndrome × azathiopurine × Other hematologic neoplasm × Clear all
NCT01190930 2026-05-28

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡